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Malaria is one of the most common parasitic diseases in the world, 
leading to over 1 million deaths/year. It mainly affects children under 
5 years of age and pregnant women and can be fatal. The most viru-
lent among the human malaria parasites is Plasmodium falciparum (Pf), 
which is responsible for the bulk of the malaria-related morbidity and 
mortality. Symptoms of uncomplicated malaria include fever, headache 
and vomiting, whereas the major complications of severe malaria in-
clude Cerebral Malaria (CM), pulmonary edema, acute renal failure 
or severe anaemia. It is characterized by the binding of Infected Red 
Blood Cell (IRBC) to the vascular endothelium (cytoadherence) and to 
non-infected erythrocytes (rosetting). The accumulation of IRBC and 
non-infected RBC generates a reduction in the blood flow of the micro-
vasculature, which results in tissue hypoxia and necrosis [1]. 
The current primary treatment for uncomplicated malaria involves 
the use of antimalarial drugs artemisinin, amodiaquine and quinine. 
Artemisinin is isolated from the plant Artemisia annua and represents, 
along with its derivatives, the most effective drug for the treatment of 
uncomplicated and severe malaria, with a rapid mechanism of action. 
Intravenous artesunate is at present the most effective treatment for 
CM. Its superiority over quinine has been recently shown with the re-
sults of the SEAQUAMAT (South East Asian Quinine Artesunate Ma-
laria Trial) and AQUAMAT study conducted in patients with CM in 
SE Asia and in Africa [2,3]. Artemisinin-Based Combination Therapy 
(ACT) is the main stay of treatment for uncomplicated malaria all over 
the world. However, there are confirmed reports of clinical resistance to 
artemisinin monotherapy and ACT from SE Asia; although the mecha-
nism is not clear yet and the phenotypic characteristics of Pf strains re-
sistant to artemisinin are unknown, these data envisage the tremendous 
risk of losing in the near future the best treatment for CM and the main 
component of ACT [4]. How such a risk could be avoided? What direc-
tions should be taken by current research? Are there any new targets 
which should be taken in account for urgent investigation and future 
clinical trials? 
Every effort should be focused in trying to develop new fast acting 
antimalarials, but also to investigate new treatment regimens or adjunct 
therapies to manage the pathogenic manifestation of the disease once 
that the ability to reduce the parasite burden will be impaired by resist-
ance or by the availability of less effective drugs. Unfortunately, to date 
there is no effective adjuvant therapy aimed at reducing symptoms of 
CM. In an effort to reduce malaria-related mortality, numerous adjunc-
tive therapies that may alter malaria-induced abnormalities in physi-
ology have been tested, as recently reviewed by John et al. [5]. These 
therapies may act directly on specific biologic pathways altered by ma-
laria or more generally on end-stage factors produced in malaria by a 
number of different specific processes. Thus, several targets were cho-
sen among factors believed to be key in the pathophysiological proc-
esses of severe malaria (e.g., elevated levels of TNFα or low levels of 
NO) or agents that control end-stage factors associated with poor clini-
cal outcomes (e.g., hypovolemia or metabolic acidosis). In a number 
of instances, these interventions were successful in reducing mortality 
in murine models of severe malaria, but results in human studies have 
been disappointing. Of all the interventions to date, only albumin infu-
sion has led to a significant decrease in mortality and this finding was 
from a single small study. 
The finding of new therapeutic targets is therefore extremely im-
portant. Recently, convincing evidence suggested that Matrix Metallo-
proteinases (MMPs) could be involved in the clinical outcome of un-
complicated towards severe malaria. These enzymes are produced by 
several cell types, including mononuclear and Endothelial Cells (EC) 
and play several functions through their proteolytic ability, including 
remodeling of sub-endothelial matrix, disruption of cerebral tight junc-
tions and activation of several pro-inflammatory molecules [6]. As re-
cently reviewed [7,8], growing evidence on the involvement of MMPs 
in severe malaria became available from our group and others in the 
last years. Data from autopsies of CM patients showed that high levels 
of MMP-1 were present within the brain, whereas in a murine model of 
CM increased expression/activity of MMP-7, -2 and -9 was observed. 
In addition, we proposed a link between human MMP and malarial 
pigment haemozoin (HZ): HZ-fed human monocytes produced in vit-
ro high levels of TNFα, IL-1β and MIP-1α that, in turn, induced MMP-
9 expression; the latter promoted the shedding into the extracellular 
environment of the soluble form of TNFα, thus creating a pathological 
loop involving inflammatory molecules and MMP. Also, it was recent-
ly shown that IRBC and HZ induced de-novo MMP-9 expression in 
human microvascular EC; and up-regulated the levels of MMP-1 and 
MMP-3 with a consequent increase in gelatinolytic activity. In all these 
systems, NF-κB activation has been reported using both HZ or IRBC 
as stimuli. 
Based on this evidence, new possible therapeutic targets for new 
adjuvant treatments for severe malaria are taking shape. The use of a 
wide-spectrum MMP-inhibitor (Batimastat, BB94) significantly in-
creased the survival of mice with CM [9]. Additionally, high doses of 
dexamethasone significantly reduced inflammation in a murine model 
of malaria-associated lung pathology [10]. Finally, natural flavonoid 
quercetin, a kinase inhibitor with anti-malarial properties, was able 
to block HZ-induced up-regulation of MMP-9, TNFα and IL-1 β [11]. 
Thus, in the next years the malaria research community should strongly 
take in account and expand the currently available knowledge on the 
role of these molecules in the etiopathogenesis of severe malaria and 
identify and test some new drugs able to inhibit these substrates, in a 
common effort aimed at finding new affordable adjuvant therapies for 
severe malaria.
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